In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

The American Diabetes Association is advising doctors and patients not to use compounded GLP-1s due to uncertainty about their content, safety, ...

Clinicians and patients should avoid using compounded GLP-1 products that are not FDA-approved, the American Diabetes Association wrote in a guidance statement published Dec. 2 in Diabetes Care. The ...

Earlier at ADA, Lilly reported phase 2 results with its once-daily oral GLP-1 agonist orforglipron, which achieved a weight reduction of almost 15% at 24 weeks, potentially giving Lilly the option ...

Medscape Medical News, June 25, 2024 ADA 2024 GLP-1 Kidney Benefits Seen With or Without SGLT2 Inhibitors Larger studies are needed because of the low numbers of patients on SGLT2 inhibitors in ...

Novo's Victoza (liraglutide) daily GLP-1 is already well established and the ... Using the American Diabetes Association (ADA) treatment target of HbA1c below or equal to 7.0%, 69% of people ...

Mizuho initiated coverage of LifeMD (LFMD) with a Neutral rating and $7 price target The firm notes that the company has succeeded due to the ...

Two studies presented at the 2024 American College of Rheumatology (ACR) Annual Meeting revealed that GLP-1 receptor agonists (GLP-1 RAs), originally for type 2 diabetes and obesity, showed ...

Germfree Laboratories, On Demand Pharmaceuticals (ODP), and North Mississippi Medical Center-Tupelo (NMMC) have teamed up to ...

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs. Doesn’t it sound like we all speak pharmacy lingo these days?